Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078131 | 0.83 | GAA (0.43) | GAAFFAR2NPY5RKDM4EALDH1A1 | |
| SCHEMBL2024919 | 0.81 | GAA (0.41) | GAAFFAR2NPY5RKDM4EALDH1A1 | |
| SCHEMBL2024918 | 0.77 | GAA (0.41) | GAANPY5RKDM4EALDH1A1NPY2R | |
| SCHEMBL3643875 | 0.73 | PSEN1 (0.36) | FFAR2 | |
| SCHEMBL2028296 | 0.73 | PSEN1 (0.36) | FFAR2 | |
| SCHEMBL1107460 | 0.72 | GAA (0.40) | GAANPY5RKDM4EALDH1A1NPY2R | |
| SCHEMBL7910584 | 0.71 | PSEN1 (0.47) | GAANPY5RALDH1A1OPRM1OPRD1 | |
| SCHEMBL8152205 | 0.70 | GAA (0.51) | GAANPY5RKDM4EALDH1A1NPY2R | |
| SCHEMBL2668154 | 0.69 | GAA (0.36) | GAAFFAR2NPY5RNPY2ROPRM1 | |
| SCHEMBL2020672 | 0.67 | GAA (0.59) | GAANPY5RKDM4EALDH1A1NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | GAA 36/4885FFAR2 4612/4885NPY5R 2086/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | GAA 157/4885FFAR2 4013/4885NPY5R 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.